GHRP-2 5mg/vial 1 Vial by Master Pharma

Usage

1. Reconstitute the Master Pharma GHRP-2 5 mg vial by injecting 2.5 ml bacteriostatic water slowly down the vial wall — do not shake; swirl gently until the lyophilised powder is fully dissolved.
2. Draw your calculated dose using a U-100 insulin syringe: 50 µl = 100 mcg, 75 µl = 150 mcg at a 2 mcg/µl solution concentration.
3. Administer subcutaneously — abdominal or thigh fat — at least 2 hours after the last meal and 30 minutes before eating post-injection to avoid blunting the GH pulse with elevated insulin.
4. During PCT, time one injection in the morning alongside your SERM dose, and a second injection 30 minutes before sleep to align with the natural nocturnal GH surge.
5. If stacking with Mod GRF(1-29) for synergistic GH output during a bridge, draw both peptides into the same syringe immediately before administration — do not pre-mix and store.
6. Store the reconstituted vial at 2–8 °C and use within 28 days; label the vial with the reconstitution date and discard on schedule regardless of remaining volume.

Warnings

Frequently asked questions

Can you use GHRP-2 during PCT without suppressing natural testosterone recovery?

Yes — GHRP-2 is fully axis-safe during PCT. It acts exclusively on the GHS-R1a receptor in the pituitary to stimulate GH pulses, and has no binding affinity for androgen receptors, oestrogen receptors, or the HPG-axis feedback nodes that SERMs are designed to rehabilitate. LH and FSH recovery proceeds unimpeded alongside GHRP-2 administration, making it one of the few anabolic-supportive peptides compatible with concurrent SERM use.

Which peptides are most suitable for a bridge phase between steroid cycles?

GHRP-2 paired with a GHRH analogue such as Mod GRF(1-29) is a standard bridge combination. The pairing produces synergistic GH pulses — each compound activates a distinct pituitary pathway — without suppressing the HPG axis or requiring post-bridge recovery. BPC-157 is sometimes added for tissue repair, but GHRP-2 alone already delivers meaningful IGF-1 elevation that supports lean mass retention during the off-cycle period.

How does GHRP-2 help protect joints after stopping anabolic steroids?

Anabolic steroids suppress natural GH pulsatility and, when withdrawn, leave a deficit in IGF-1 — the primary driver of collagen and proteoglycan synthesis in connective tissue. GHRP-2 restores pulsatile GH secretion, re-elevating IGF-1 and thereby supporting synovial repair. Athletes commonly report reduced shoulder and elbow discomfort within 3–4 weeks of consistent GHRP-2 use post-cycle, consistent with IGF-1's documented role in cartilage matrix maintenance.

How do I dose Master Pharma GHRP-2 5mg/vial using an insulin syringe, and how long does one vial last?

Reconstitute the 5 mg vial with 2.5 ml bacteriostatic water to yield a 2 mcg/µl solution. A standard 100 mcg dose draws to the 50 µl (0.05 ml) mark on a U-100 insulin syringe; a 150 mcg dose to 75 µl. At three injections daily of 100 mcg, one 5 mg vial provides approximately 16–17 days of supply — making it ideal for precise low-dose PCT titration without leftover waste from a higher-concentration vial.

How should Master Pharma GHRP-2 be stored after reconstitution, and what is its shelf life once opened?

Lyophilised GHRP-2 vials should be stored at 2–8 °C refrigerated and away from direct light; unopened, stability extends to the printed expiry date. After reconstitution with bacteriostatic water, the solution remains stable for up to 28 days when refrigerated at 2–8 °C. Do not freeze the reconstituted solution, as freeze–thaw cycles degrade peptide integrity. Discard any vial showing visible particulates or colour change. (2) angle_used

Manufacturer

Formulation science at Master Pharma extends beyond active-ingredient purity to the carrier and excipient decisions that govern stability, reconstitution behaviour, and injection tolerability. For lyophilised peptide vials including GHRP-2, the excipient selection — predominantly mannitol as a lyoprotectant combined with a controlled residual moisture target below 1 % — determines both the structural integrity of the peptide cake and the ease of reconstitution in the field. These auxiliary substance parameters are not incidental; each batch specification defines acceptable limits for residual solvent, endotoxin contribution from excipient sources, and osmolality of the reconstituted solution, all cross-verified through LAL testing and HPLC identity confirmation before a lot receives release authorisation. The result is a vial format where the declared 5 mg active content and the surrounding matrix behave predictably batch to batch — a consistency that underpins Top Seller status in a product category where excipient-related degradation is a documented failure mode.